Treatment of Colonic-Type Adenocarcinoma of the Appendix

Colonic-type adenocarcinoma arising in the appendix is managed along the same lines as colon cancer. Workup, staging, and treatment decisions in this histological subtype follow colon cancer principles, with nodal status and stage-specific risk features driving adjuvant therapy decisions.

Clinical scenario

This protocol addresses colonic-type adenocarcinoma of the appendix — one of the recognised appendix cancer subtypes. For this histotype, staging and treatment mirror those of colon-primary adenocarcinoma. Nodal involvement and the adequacy of nodal staging are central to treatment planning.

Treatment approach (partial overview)

Adjuvant systemic chemotherapy is a core consideration for eligible patients, with the indication shaped by nodal status and, in earlier stages, the presence of high-risk features — including patient age and adequacy of nodal staging.

Full regimen details, drug selection, and decision criteria are in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1055/s-0035-1564433

For the purposes of this review, appendix cancers will be broadly classified as: colonic-type adenocarcinoma, mucinous adenocarcinoma, goblet cell adenocarcinoma (GCA), and neuroendocrine carcinoma (aka. "typical carcinoid").
The workup, staging, and treatment of colonic-type adenocarcinoma arising in the appendix mirror that of colon cancer.
Patients with node-positive disease (stage III) warrant adjuvant systemic chemotherapy with 5-fluorouracil/leucovorin or capecitabine with oxaliplatin if medically fit.
As for colon-primary adenocarcinoma, adjuvant chemotherapy should also be considered for stage II patients with high-risk features, especially younger patients and those with inadequate nodal staging.

View source ↗